{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T05:09:01Z","timestamp":1795064941710,"version":"4.10.2"},"reference-count":43,"publisher":"American Association for Cancer Research (AACR)","issue":"21","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The taccalonolides are a class of structurally and mechanistically distinct microtubule-stabilizing agents isolated from Tacca chantrieri. A crucial feature of the taxane family of microtubule stabilizers is their susceptibility to cellular resistance mechanisms including overexpression of P-glycoprotein (Pgp), multidrug resistance protein 7 (MRP7), and the \u03b2III isotype of tubulin. The ability of four taccalonolides, A, E, B, and N, to circumvent these multidrug resistance mechanisms was studied. Taccalonolides A, E, B, and N were effective in vitro against cell lines that overexpress Pgp and MRP7. In addition, taccalonolides A and E were highly active in vivo against a doxorubicin- and paclitaxel-resistant Pgp-expressing tumor, Mam17\/ADR. An isogenic HeLa-derived cell line that expresses the \u03b2III isotype of tubulin was generated to evaluate the effect of \u03b2III-tubulin on drug sensitivity. When compared with parental HeLa cells, the \u03b2III-tubulin\u2013overexpressing cell line was less sensitive to paclitaxel, docetaxel, epothilone B, and vinblastine. In striking contrast, the \u03b2III-tubulin\u2013overexpressing cell line showed greater sensitivity to all four taccalonolides. These data cumulatively suggest that the taccalonolides have advantages over the taxanes in their ability to circumvent multiple drug resistance mechanisms. The ability of the taccalonolides to overcome clinically relevant mechanisms of drug resistance in vitro and in vivo confirms that the taccalonolides represent a valuable addition to the family of microtubule-stabilizing compounds with clinical potential. [Cancer Res 2008;68(21):8881\u20138]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-2037","type":"journal-article","created":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T03:57:40Z","timestamp":1225339060000},"page":"8881-8888","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["The Taccalonolides: Microtubule Stabilizers That Circumvent Clinically Relevant Taxane Resistance Mechanisms"],"prefix":"10.1158","volume":"68","author":[{"given":"April L.","family":"Risinger","sequence":"first","affiliation":[{"name":"1Department of Physiology and Medicine, Southwest Foundation for Biomedical Research;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn M.","family":"Jackson","sequence":"additional","affiliation":[{"name":"1Department of Physiology and Medicine, Southwest Foundation for Biomedical Research;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Polin","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Helms","sequence":"additional","affiliation":[{"name":"4Nuclear Magnetic Resonance Center, Washington State University, Pullman, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree A.","family":"LeBoeuf","sequence":"additional","affiliation":[{"name":"1Department of Physiology and Medicine, Southwest Foundation for Biomedical Research;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Joe","sequence":"additional","affiliation":[{"name":"2Department of Biochemistry, University of Texas Health Science Center, San Antonio, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hopper-Borge","sequence":"additional","affiliation":[{"name":"5Department of Medicine and Cancer Center, University of Illinois at Chicago Cancer Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Luduen\u0303a","sequence":"additional","affiliation":[{"name":"2Department of Biochemistry, University of Texas Health Science Center, San Antonio, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Kruh","sequence":"additional","affiliation":[{"name":"5Department of Medicine and Cancer Center, University of Illinois at Chicago Cancer Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Mooberry","sequence":"additional","affiliation":[{"name":"1Department of Physiology and Medicine, Southwest Foundation for Biomedical Research;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,10,30]]},"reference":[{"key":"2022061700274015000_B1","unstructured":"Rowinsky EK, Tolcher AW. Antimicrotubule agents. In: DeVita VTJ, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. Philadelphia (PA): Lippincott, Williams and Wilkins; 2001. p. 431\u201347."},{"key":"2022061700274015000_B2","doi-asserted-by":"crossref","unstructured":"Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer\u20082004; 4: 253\u201365.","DOI":"10.1038\/nrc1317"},{"key":"2022061700274015000_B3","doi-asserted-by":"crossref","unstructured":"Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets\u20082007; 7: 730\u201342.","DOI":"10.2174\/156800907783220417"},{"key":"2022061700274015000_B4","doi-asserted-by":"crossref","unstructured":"Chu Q, Vincent M, Logan D, Mackay J, Evans W. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer\u20082005; 50: 355\u201374.","DOI":"10.1016\/j.lungcan.2005.06.010"},{"key":"2022061700274015000_B5","doi-asserted-by":"crossref","unstructured":"Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol\u20082005; 6: 229\u201339.","DOI":"10.1016\/S1470-2045(05)70094-2"},{"key":"2022061700274015000_B6","doi-asserted-by":"crossref","unstructured":"Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol\u20082007; 18: 3\u20138.","DOI":"10.1093\/annonc\/mdm172"},{"key":"2022061700274015000_B7","doi-asserted-by":"crossref","unstructured":"Conlin A, Fornier M, Hudis C, Kar S, Kirkpatrick P. Ixabepilone. Nat Rev Drug Discov\u20082007; 6: 953\u201354.","DOI":"10.1038\/nrd2469"},{"key":"2022061700274015000_B8","doi-asserted-by":"crossref","unstructured":"Mita A, Lockhart AC, Chen T-L, et al. A phase I pharmacokinetic (PK) trial of XAA296A (discodermolide) administered every 3 wks to adult patients with advance solid malignancies. J Clin Oncol\u20082004; 22: 2025.","DOI":"10.1200\/jco.2004.22.90140.2025"},{"key":"2022061700274015000_B9","unstructured":"Tinley TT, Randall-Hlubek DA, Leal RM, et al. Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity. Cancer Res\u20082003; 63: 3211\u201320."},{"key":"2022061700274015000_B10","doi-asserted-by":"crossref","unstructured":"Buey RM, Barsoain I, Jackson E, et al. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the Taxol site predicts cytotoxicity. Chem Biol\u20082005; 12: 1269\u201379.","DOI":"10.1016\/j.chembiol.2005.09.010"},{"key":"2022061700274015000_B11","doi-asserted-by":"crossref","unstructured":"Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem\u20082002; 71: 537\u201392.","DOI":"10.1146\/annurev.biochem.71.102301.093055"},{"key":"2022061700274015000_B12","doi-asserted-by":"crossref","unstructured":"Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist\u20082003; 8: 411\u201324.","DOI":"10.1634\/theoncologist.8-5-411"},{"key":"2022061700274015000_B13","doi-asserted-by":"crossref","unstructured":"Rottenberg S, Nygren AOH, Pajic M, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A\u20082007; 104: 12117\u201322.","DOI":"10.1073\/pnas.0702955104"},{"key":"2022061700274015000_B14","doi-asserted-by":"crossref","unstructured":"Borst P, Jonkers J, Rottenberg S. What makes tumors multidrug resistant? Cell Cycle\u20082007; 6: 2782\u20137.","DOI":"10.4161\/cc.6.22.4936"},{"key":"2022061700274015000_B15","doi-asserted-by":"crossref","unstructured":"Yeh JJ, Hsu WH, Wang JJ, Ho ST, Kao A. Predicting chemotherapy response to Taxol-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration\u20082003; 70: 32\u20135.","DOI":"10.1159\/000068411"},{"key":"2022061700274015000_B16","doi-asserted-by":"crossref","unstructured":"Chiou J-F, Liang J-A, Hsu W-H, Wang J-J, Ho S-T, Kao A. Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung\u20082003; 181: 267\u201373.","DOI":"10.1007\/s00408-003-1029-7"},{"key":"2022061700274015000_B17","doi-asserted-by":"crossref","unstructured":"Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1\/gp170 expression and its possible functional significance. J Natl Cancer Inst\u20081997; 89: 917\u201331.","DOI":"10.1093\/jnci\/89.13.917"},{"key":"2022061700274015000_B18","doi-asserted-by":"crossref","unstructured":"Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR, Kruh GD. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett\u20082001; 162: 181\u201391.","DOI":"10.1016\/S0304-3835(00)00646-7"},{"key":"2022061700274015000_B19","doi-asserted-by":"crossref","unstructured":"Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol\u20082003; 63: 351\u20138.","DOI":"10.1124\/mol.63.2.351"},{"key":"2022061700274015000_B20","doi-asserted-by":"crossref","unstructured":"Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res\u20082004; 64: 4927\u201330.","DOI":"10.1158\/0008-5472.CAN-03-3111"},{"key":"2022061700274015000_B21","doi-asserted-by":"crossref","unstructured":"Dabrowska M, Sirotnak FM. Regulation of transcription of the human MRP7 gene. Characteristics of the basal promoter and identification of tumor-derived transcripts encoding additional 5\u2032 end heterogeneity. Gene\u20082004; 341: 129\u201339.","DOI":"10.1016\/j.gene.2004.06.022"},{"key":"2022061700274015000_B22","unstructured":"Takayanagi S, Kataoka T, Ohara O, Oishi M, Kuo MT, Ishikawa T. Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent up-regulation. J Exp Ther Oncol\u20082004; 4: 239\u201346."},{"key":"2022061700274015000_B23","doi-asserted-by":"crossref","unstructured":"Oguri T, Ozasa H, Uemura T, et al. MRP7\/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther\u20082008; 7: 1150\u20135.","DOI":"10.1158\/1535-7163.MCT-07-2088"},{"key":"2022061700274015000_B24","doi-asserted-by":"crossref","unstructured":"Seve P, Dumontet C. Is class III \u03b2-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol\u20082008; 9: 168\u201375.","DOI":"10.1016\/S1470-2045(08)70029-9"},{"key":"2022061700274015000_B25","doi-asserted-by":"crossref","unstructured":"Panda D, Miller HP, Banerjee A, Luduen\u0303a RF, Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A\u20081994; 91: 11358\u201362.","DOI":"10.1073\/pnas.91.24.11358"},{"key":"2022061700274015000_B26","doi-asserted-by":"crossref","unstructured":"Lu Q, Luduen\u0303a RF. Removal of \u03b2 III isotype enhances Taxol induced microtubule assembly. Cell Struct Funct\u20081993; 18: 173\u201382.","DOI":"10.1247\/csf.18.173"},{"key":"2022061700274015000_B27","doi-asserted-by":"crossref","unstructured":"Kamath K, Wilson L, Cabral F, Jordan MA. \u03b2III-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem\u20082005; 280: 12902\u20137.","DOI":"10.1074\/jbc.M414477200"},{"key":"2022061700274015000_B28","doi-asserted-by":"crossref","unstructured":"Gan PP, Pasquier E, Kavallaris M. Class III \u03b2-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res\u20082007; 67: 9356\u201363.","DOI":"10.1158\/0008-5472.CAN-07-0509"},{"key":"2022061700274015000_B29","doi-asserted-by":"crossref","unstructured":"Chen Z-L, Shen J-H, Gao Y-S. Some chemical reactions of taccalonolide A\u2014a bitter substance from Tacca plantaginea. Heterocycles\u20081989; 29: 2103\u20138.","DOI":"10.3987\/COM-89-5101"},{"key":"2022061700274015000_B30","doi-asserted-by":"crossref","unstructured":"Sadava D, Coleman A, Kane SE. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res\u20082002; 12: 301\u20139.","DOI":"10.1081\/LPR-120016196"},{"key":"2022061700274015000_B31","doi-asserted-by":"crossref","unstructured":"Joe PA, Banerjee A, Luduen\u0303a RF. The roles of Cys124 and Ser239 in the functional properties of human \u03b2III tubulin. Cell Motil Cytoskeleton\u20082008; 65: 476\u201386. Epub 2008 Apr 24.","DOI":"10.1002\/cm.20274"},{"key":"2022061700274015000_B32","doi-asserted-by":"crossref","unstructured":"Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer discovery screen. Drug Dev Res\u20081995; 34: 91\u2013109.","DOI":"10.1002\/ddr.430340203"},{"key":"2022061700274015000_B33","doi-asserted-by":"crossref","unstructured":"Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst\u20081990; 82: 1107\u201312.","DOI":"10.1093\/jnci\/82.13.1107"},{"key":"2022061700274015000_B34","doi-asserted-by":"crossref","unstructured":"Banerjee A, Roach MC, Trcka P, Luduen\u0303a RF. Preparation of a monoclonal antibody specific for the class IV isotype of \u03b2-tubulin. Purification and assembly of \u03b1\u03b2II, \u03b1\u03b2III, and \u03b1\u03b2IV tubulin dimers from bovine brain. J Biol Chem\u20081992; 267: 5625\u201330.","DOI":"10.1016\/S0021-9258(18)42811-6"},{"key":"2022061700274015000_B35","doi-asserted-by":"crossref","unstructured":"Weiderhold KN, Randall-Hlubek DA, Polin LA, Hamel E, Mooberry SL. CB694, a novel antimitotic with antitumor activities. Int J Cancer\u20082006; 118: 1032\u201340.","DOI":"10.1002\/ijc.21424"},{"key":"2022061700274015000_B36","doi-asserted-by":"crossref","unstructured":"Corbett T, Polin L, Roberts BJ, et al. Transplantable syngeneic rodent tumors: solid tumors in mice. In: Teicher BA, editor. Tumor models in cancer research. Totowa (NJ): Humana Press; 2002.","DOI":"10.1007\/978-1-59259-100-8_3"},{"key":"2022061700274015000_B37","doi-asserted-by":"crossref","unstructured":"Schumacher G, Hoffmann J, Cramer T, et al. Antineoplastic activity of 2-methoxyestradiol in human pancreatic and gastric cancer cells with different multidrug-resistant phenotypes. J Gastroenterol Hepatol\u20082007; 22: 1469\u201373.","DOI":"10.1111\/j.1440-1746.2007.05033.x"},{"key":"2022061700274015000_B38","doi-asserted-by":"crossref","unstructured":"Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III \u03b2-tubulin reduces microtubule assembly and confers resistance to Taxol. Cell Motil Cytoskeleton\u20082003; 56: 45\u201356.","DOI":"10.1002\/cm.10132"},{"key":"2022061700274015000_B39","doi-asserted-by":"crossref","unstructured":"Fellous A, Francon J, Lennon AM, Nunez J. Microtubule assembly in vitro. Purification of assembly-promoting factors. Eur J Biochem\u20081977; 78: 167\u201374.","DOI":"10.1111\/j.1432-1033.1977.tb11726.x"},{"key":"2022061700274015000_B40","doi-asserted-by":"crossref","unstructured":"Banerjee A, Roach MC, Wall KA, Lopata MA, Cleveland DW, Luduen\u0303a RF. A monoclonal antibody against the type II isotype of \u03b2-tubulin. Preparation of isotypically altered tubulin. J Biol Chem\u20081988; 263: 3029\u201334.","DOI":"10.1016\/S0021-9258(18)69171-9"},{"key":"2022061700274015000_B41","unstructured":"Luduen\u0303a R, Banerjee A. The isotypes of tubulin: distribution and functional significance. In: Fojo T, editor. Microtubules. Totowa (NJ): Humana Press; 2005."},{"key":"2022061700274015000_B42","doi-asserted-by":"crossref","unstructured":"Furuta E, Pai SK, Zhan R, et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res\u20082008; 68: 1003\u201311.","DOI":"10.1158\/0008-5472.CAN-07-2489"},{"key":"2022061700274015000_B43","doi-asserted-by":"crossref","unstructured":"Raspaglio G, Filippetti F, Prislei S, et al. Hypoxia induces class III \u03b2-tubulin gene expression by HIF-1\u03b1 binding to its 3\u2032 flanking region. Gene\u20082008; 409: 100\u20138.","DOI":"10.1016\/j.gene.2007.11.015"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/21\/8881\/2598596\/8881.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/21\/8881\/2598596\/8881.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T07:18:10Z","timestamp":1738480690000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/21\/8881\/541768\/The-Taccalonolides-Microtubule-Stabilizers-That"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,30]]},"references-count":43,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2008,10,30]]},"published-print":{"date-parts":[[2008,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-2037","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22376400.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376406.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376400","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376409.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376403","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376403.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6498192.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376406","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376409","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6498192","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,30]]}}}